Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Cagrilintide in Japanese and Caucasian Men
NCT03787225Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2019
- Primary completion
- Jun 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of cagrilintide in obesity and Overweight (4 arms), sponsored by Novo Nordisk. Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity at Day 36. Started Jan 2019; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03787225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03787225.